Daewon Pharmaceutical announced on the 14th that it will conduct regular open recruitment for new and experienced employees in the first half of 2023.


[Image courtesy of Daewon Pharmaceutical]

[Image courtesy of Daewon Pharmaceutical]

View original image

The recruitment fields include ▲ Sales (ETC/OTC/CHC) ▲ Marketing (ETC/Academic) ▲ R&D (BD/Clinical/MW/PV/Synthetic Research/Pharmacological Research/Evaluation Research/Formulation Research/Health Functional Foods) ▲ ICT Support Department (Information Development) ▲ Hyangnam Plant (Analysis/Pharmacist in Charge/Manufacturing Equipment/Raw Material Management) ▲ Jincheon Plant (Pharmacist in Charge/Manufacturing Equipment/Manufacturing), etc.


This recruitment process selects the final successful candidates through document screening, followed by aptitude tests, first-round practical interviews, and second-round executive interviews.


'Daewon Pharmaceutical DNA Recruitment' is a hiring system operated by Daewon Pharmaceutical since 2021, meaning it seeks talents who possess the DNA of Daewon employees through competency-based recruitment rather than focusing on credentials. It emphasizes common competencies required as Daewon Pharmaceutical employees and job competencies suitable for each role as core values.


Daewon Pharmaceutical operates online recruitment briefings and consultation sessions. On the 15th, a non-face-to-face recruitment briefing and job introduction corner will be held via YouTube live broadcast, and on the 16th, an online consultation session will be conducted through KakaoTalk open chat. Additionally, interview videos featuring current employees discussing company life, job pros and cons, and tips for success can be viewed on Daewon Pharmaceutical’s official YouTube channel.



The deadline for document submission is until 5:30 PM on the 20th. For more details, please check the Daewon Pharmaceutical recruitment website.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing